NCT02900027View on ClinicalTrials.gov

Safety, Tolerability, PK, and Pharmacodynamics(PD) of IONIS APOCIII-LRx in Healthy Volunteers With Elevated Triglycerides

PHASE1CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

September 30, 2016

Primary Completion Date

April 30, 2018

Study Completion Date

April 30, 2018

Conditions
Elevated Triglycerides (TG)
Interventions
DRUG

APOC-III-L-Rx

Ascending single and multiple doses of IONIS-APOC-III-LRx by subcutaneous (SC) injection

DRUG

Placebo Comparator

Sterile Normal Saline (0.9% NaCl) calculated volume to match active comparator

Trial Locations (1)

M9L 3A2

BioPharma Services, Toronto

Sponsors

Collaborators (1)

Akcea Therapeutics
All Listed Sponsors
collaborator

Akcea Therapeutics

INDUSTRY

lead

Ionis Pharmaceuticals, Inc.

INDUSTRY

NCT02900027 - Safety, Tolerability, PK, and Pharmacodynamics(PD) of IONIS APOCIII-LRx in Healthy Volunteers With Elevated Triglycerides | Biotech Hunter | Biotech Hunter